<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="119306">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01851070</url>
  </required_header>
  <id_info>
    <org_study_id>MSB-RA001</org_study_id>
    <nct_id>NCT01851070</nct_id>
  </id_info>
  <brief_title>A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNF Alpha Inhibitor</brief_title>
  <official_title>A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNF Alpha Inhibitor.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mesoblast, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mesoblast, Ltd.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study is a double-blind, randomized, placebo controlled, dose escalating study.  The primary
      objective of this study is to evaluate the safety, tolerability and feasibility of a single
      intravenous infusion of allogeneic mesenchymal precursor cells (MPCs) compared to placebo at
      12 weeks post-infusion in the treatment of patients with active rheumatoid arthritis (RA)
      who have received methotrexate +/- other DMARDs for at least 6 months prior to screening and
      who have had an incomplete response to at least one TNF-alpha inhibitor.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Evaluation of the safety of a single IV infusion of allogeneic MPCs compared to placebo at 12 weeks post-infusion</measure>
    <time_frame>12 weeks post IV Infusion</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To evaluate the safety, tolerability and feasibility of a single intravenous (IV) infusion of allogeneic mesenchymal precursor cells (MPCs) compared to placebo at 12 weeks post-infusion in the treatment of patients with active rheumatoid arthritis (RA) who have received methotrexate +/- other oral DMARDs for at least 6 months and who have had an incomplete response to at least one course of a TNFα inhibitor.
Overall safety will be based on the overall assessment of AE/SAEs, Vital Signs, Physical Examination, clinical laboratory tests, ECGs, pulmonary function tests and Chest x-ray.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Demonstration of efficacy of allogeneic MPCs compared to placebo at 12 weeks post-infusion with MPCs or placebo in the treatment of patients with active rheumatoid arthritis</measure>
    <time_frame>12 weeks post IV infusion with MPCs</time_frame>
    <safety_issue>No</safety_issue>
    <description>Efficacy will be assessed according to the following criteria:
ACR20/50/70
Mean changes from baseline in DAS28 (hsCRP)
Mean changes from baseline in all components of the ACR core response criteria:  Swollen joint count, Tender joint count, Investigator global assessment of disease activity (VAS), Patient global assessment of disease activity (VAS), Patient reported pain (VAS), Health Assessment Questionnaire (HAQ-DI), ESR or hsCRP
Remissions (as defined in the 2011 Joint Statement of the American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term evaluation of safety and efficacy of a singly IV infusion of allogeneic MPCs in patients with active RA who have received methotrexate +/- other DMARDs for at least 6 months and who have had an incomplete response to at least one TNF-alpha inhi</measure>
    <time_frame>78 weeks post IV Infusion</time_frame>
    <safety_issue>No</safety_issue>
    <description>Safety will be assessed according to the following:
Adverse events/serious adverse events (&quot;primary endpoint&quot;)
Vital signs
Physical examination
Clinical laboratory tests
Electrocardiogram
Pulmonary function tests
Chest x-ray (CXR)
Efficacy will be assessed according to the following:
ACR 20/50/70
DAS28 (mean changes from baseline as measured by using hsCRP)
Mean changes from baseline in all components of the ACR core response criteria
Remissions (as defined in the 2011 Joint Statement of the American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR)
Joint erosion of hands and wrists assessed via x-ray
Patient-reported outcomes
SF36v2
HAQ_DI</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Normal Saline Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be delivered in 100 mL normal saline administered intravenously over approximately 45 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Allogeneic Mesenchymal Precursor Cells</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mesenchymal Precursor Cells (MPCs), either 1.0 or 2.0 million cells/kg, will be delivered in 100 mL normal saline administered intravenously over approximately 45 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allogeneic Mesenchymal Precursor Cells</intervention_name>
    <arm_group_label>Normal Saline Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <arm_group_label>Allogeneic Mesenchymal Precursor Cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and Females ages 18-80 years old

          -  Active rheumatoid arthritis (RA) disease as per 2010 ACR/EULAR classification
             criteria for the diagnosis of RA.

          -  Must be positive for rheumatoid factor and/or anti-cyclic citrullinated peptide
             (anti-CCP3) but without extra-articular disease or functional limitation

          -  Patient with active RA defined as:

               -  4 tender joints (TJC) count (28 joint count) at screening and

               -  4 swollen joints (SJC) count (28 joint count) at screening

          -  ESR ≥ 28 mm/hr OR hsCRP greater than ULN

          -  Patient has been taking MTX for at least 6 months with dose and route of
             administration stable for at least 8 weeks prior to screening

          -  Patient has had an inadequate response to at least one TNFα inhibitor with last dose
             at least 6 weeks prior to screening

          -  Use of oral DMARD (sulfasalazine, hydroxychloroquine, chloroquine and leflunomide) is
             permitted but must be stable for at least 3 months prior to screening

        Exclusion Criteria:

          -  Pregnant women or women who are breastfeeding.

          -  Other investigational therapy received within 8 weeks or five half-lives (whichever
             is longer) prior to Screening (except as in exclusion #13).

          -  Known or suspected alcohol or drug abuse within three years preceding Screening.

          -  Autoimmune disease other than RA (such as systemic lupus erythematosus (SLE), mixed
             connective tissue disease, scleroderma, polymyositis/dermatomyositis, vasculitis)

          -  History of or current inflammatory joint disease other than RA (such as tophaceous
             gout, reactive arthritis, psoriatic arthritis, ankylosing spondylitis or other
             spondyloarthropathy, Lyme disease). Patients primarily diagnosed with osteoarthritis
             are excluded.

          -  Bedridden or confined to a wheelchair or patients with &gt; 3 arthroplasties due to RA.

          -  History of diagnosed and/or treated malignancy (except for treated basal cell or
             squamous cell carcinoma of the skin or cervical carcinoma in situ with no evidence of
             recurrence).

          -  Surgical procedures planned to occur during the trial (these patients may be
             rescreened following completion of and recovery from the surgical procedure).

          -  Use of TNFα inhibitor for treatment of RA at time of screening or within the 6 weeks
             prior to screening.

          -  Prior use of more than two biologics in addition to TNFα inhibitors for treatment of
             RA.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Pinnacle Research Group</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>April Bolt</last_name>
      <phone>256-236-0055</phone>
      <phone_ext>111</phone_ext>
      <email>abolt@pinnacletrials.com</email>
    </contact>
    <investigator>
      <last_name>Vishala Chindalore, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arthrocare Arthritis Care and Research PC</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chanel Tate</last_name>
      <phone>480-245-7663</phone>
      <email>research3@arthrocarepc.com</email>
    </contact>
    <investigator>
      <last_name>Michael Fairfax, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nashla Barroso</last_name>
      <phone>310-825-9682</phone>
      <email>nbarroso@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Daniel Furst, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inland Rheumatology Clinical Trials Incorporated</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91786</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Alvarez</last_name>
      <phone>909-296-8701</phone>
      <email>calvarez@irclinicaltrials.com</email>
    </contact>
    <investigator>
      <last_name>Antony Hou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ocala Rheumatology Research Center</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34474</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathryn Vallance</last_name>
      <phone>352-861-6931</phone>
      <email>kathrynvallancecrc@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Stephen Bookbinder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arthritis Center</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <zip>34684</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shonte Jones</last_name>
      <phone>727-789-2784</phone>
      <phone_ext>23</phone_ext>
      <email>sjones@arthritiscenter.org</email>
    </contact>
    <investigator>
      <last_name>Mitchell Lowenstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarasota Arthritis Research Center</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tasha Smalls</last_name>
      <phone>941-366-1244</phone>
      <email>tsmalls.sarc@comcast.net</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Kaine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>JHU Arthritis Center Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marilyn Towns</last_name>
      <phone>410-550-0579</phone>
      <email>mctowns@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Clifton Bingham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arthritis Treatment Center</name>
      <address>
        <city>Frederick</city>
        <state>Maryland</state>
        <zip>21702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary L Strieter</last_name>
      <phone>301-624-1167</phone>
      <email>mstrieter@arthritistreatmentcenter.com</email>
    </contact>
    <investigator>
      <last_name>Nathan Wei, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Reliant Medical Group</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcia Kirkpatrick</last_name>
      <phone>508-556-5429</phone>
      <email>marcia.kirkpatrick@reliantmedicalgroup.org</email>
    </contact>
    <investigator>
      <last_name>John Hosey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heidi Hanf</last_name>
      <phone>507-266-4175</phone>
      <email>hanf.heidi@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Eric L Matteson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Office of Ramesh C. Gupta, MD</name>
      <address>
        <city>Fair Lawn</city>
        <state>New Jersey</state>
        <zip>07410</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Manju Gupta</last_name>
      <phone>901-681-9670</phone>
      <email>smartmanju@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Ramesh Gupta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>DJL Clinical Research</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia Nagaeva</last_name>
      <phone>704-541-9092</phone>
      <phone_ext>212</phone_ext>
      <email>julianagaeva@boxarthritis.com</email>
    </contact>
    <investigator>
      <last_name>Emily Box, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Health Research of Oklahoma</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Crista Bowling</last_name>
      <phone>405-702-6770</phone>
      <email>cbowling@healthresearchok.com</email>
    </contact>
    <investigator>
      <last_name>Christine Codding, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15261</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dawn McBride</last_name>
      <phone>412-648-9413</phone>
      <email>mcbridedl@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Larry Moreland, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Tennessee Research Institute</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trina Lawrence</last_name>
      <phone>731-951-0249</phone>
      <email>tlawrence@arthritisclinic.org</email>
    </contact>
    <investigator>
      <last_name>Jacob Aelion, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Accurate Clinical Research</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77034</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ronald Obmaces</last_name>
      <phone>281-481-8557</phone>
      <email>robmaces@accurateclinicalresearch.com</email>
    </contact>
    <investigator>
      <last_name>Philip Waller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 12, 2014</lastchanged_date>
  <firstreceived_date>April 19, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
